SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Dec 30, 2015
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Dec. 30, 2015 · CIK: 0001390478 · Accession: 0001193125-15-418037
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-208331
Letter
Re: Galena Biopharma, Inc.; Post-Effective Amendment No. 1 to Registration Statement on Form S-3 (Reg. No. 333-208331)
December 30, 2015
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-6010
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc., a Delaware corporation (“Galena”), respectfully requests that the effective date of the Post-Effective Amendment referred to above be accelerated to 5:00 P.M., Washington, D.C. time, Thursday, December 31, 2015, or as soon thereafter as is practicable.
In making its request, Galena acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve Galena from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
Galena may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Galena Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 30, 2015 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Galena Biopharma, Inc.; Post-Effective Amendment No. 1 to Registration Statement on Form S-3 (Reg. No. 333-208331) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Galena Biopharma, Inc., a Delaware corporation (“Galena”), respectfully requests that the effective date of the Post-Effective Amendment referred to above be accelerated to 5:00 P.M., Washington, D.C. time, Thursday, December 31, 2015, or as soon thereafter as is practicable. In making its request, Galena acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve Galena from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • Galena may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Galena Biopharma, Inc. By: /s/ Mark W. Schwartz Mark W. Schwartz, Ph.D. President and Chief Executive Officer